Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine is under clinical development by FluGen and currently in Phase I for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H3N2 Subtype Infections have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine overview
Influenza vaccine is under development for the prevention of influenza A strain H3N2 infections. It is administered through intranasal route. The drug candidate is a monovalent vaccine derived from Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR strain.
FluGen is a developer of influenza vaccines and therapies. The company discovers, develops, and commercializes new methods for the prevention and treatment of influenza infections. Its product includes redeeflu, a nasal spray vaccine used to protect against influenza that contains mutations in the M2 gene of the virus. FluGen’s redeeflu provides better efficacy against seasonal and pandemic influenza and protection against future pandemic strains. Its redeeflu viruses infect cells, express the entire spectrum of influenza RNA and proteins but cannot produce any infectious virus particles. The company conducts research and development activities with various research facilities. FluGen is headquartered in Madison, Wisconsin, the US.
For a complete picture of Influenza [strain A/Singapore/INFIMH-16-0019/2016 (H3N2)] (monovalent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.